Piper Sandler analyst Michael Lavery maintained an Overweight rating on Colgate-Palmolive and raised the price target to $96 from $92. Wells Fargo analyst Chris Carey also maintained an Equal-Weight rating on the stock, increasing the price target to $95 from $92. The adjustments reflect revised outlooks on the consumer goods giant's valuation.

Rating and Target Details

The research notes confirm the brokerages' stances while updating their price objectives. Piper Sandler's new target of $96 represents a $4 increase from the previous mark, while Wells Fargo's target of $95 is a $3 rise.

Citi has reiterated its Sell rating on Colgate-Palmolive (India), lowering its target price to ₹1,900 from ₹2,050. The revision reflects the brokerage's concerns over the company's medium-term earnings trajectory, as competitive pressures continue to weigh on the overall growth outlook.

Revised Target and Key Rationale

The target price cut underscores Citi's cautious stance on the stock. While the brokerage acknowledged balanced revenue growth and some contribution from pricing gains, it noted that these positives are being offset by intensifying competition in the market. The following table summarises the key details of Citi's revised call:

Factors Behind the Downgrade in Target

Citi's revised assessment is driven by a combination of factors that temper the company's near-term prospects:

• Balanced revenue growth: The brokerage noted revenue growth remains balanced, without a strong upside catalyst.
• Pricing gains offset by competition: While pricing has contributed positively, intense competitive activity in the segment limits the net benefit.
• Lower valuation multiple: Citi applied a lower valuation multiple to its estimates, reflecting weaker-than-expected medium-term earnings growth.

The combination of these factors has led the brokerage to reduce its target price, maintaining its overall negative outlook on the stock. The emphasis on a lower valuation multiple signals that Citi views the current earnings growth profile as insufficient to justify a higher price target for Colgate-Palmolive (India).